leadf
logo-loader
viewPureTech Health
(
LSE:PRTCNASDAQ:PRTCOTC:PTCHFFRA:0VQ
)

PureTech Health surges as Karuna investment rockets 442%

The Nasdaq-listed company soared after announcing that its lead asset KarXT reported an above-average result in phase II of trials on schizophrenic patients

PureTech Health plc - PureTech Health rallies over affiliate Karuna Therapeutics’ success
PureTech owns a 31.6% stake in the US company

PureTech Health plc (LON:PRTC) shares shot higher on Tuesday after its 32%-owned investment Karuna Therapeutics Inc (NASDAQ:KRTX) enjoyed a whopping 442% leap overnight.

The Nasdaq-listed biopharma company soared after announcing that its lead asset KarXT reported an above-average result in phase II of trials on schizophrenic patients, paving the way for regulatory approval.

READ: PureTech shares jump as Gelesis approval caps “transformational” six months

Karuna’s stock closed at US$96 on Monday, more than five times higher than Friday’s price, valuing the company at US$2.2bn.

PureTech saw its 31.6% stake in the US company rise to US$580mln from US$130mln at the end of last week, although its share price went up only 13%, compared to the 70% expected by broker Peel Hunt.

“This valuation dislocation is unsustainable in our view,” analysts said in a note.

“We see this as one of the most meaningful catalysts for PureTech in the near to medium term, and a strong result in this very difficult to treat disease.”

Shares in PureTech kept growing on Tuesday, jumping 16% to 289.66p in the morning.

Quick facts: PureTech Health

Follow
LSE:PRTC

Price: 356 GBX

Market Cap: £1.02 billion

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of named herein, including the promotion by the Company of in any Content on the Site, the Company receives from said issuer annual cash...

FOR OUR FULL DISCLAIMER CLICK HERE

PureTech Health advances to late-stage clinical trials as it builds strong...

PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) is a clinical-stage biotherapeutics company dedicated to discovering, developing and commercializing highly differentiated medicines for devastating diseases. CEO and founder Daphne Zohar joined Proactive’s Stephen Gunnion to discuss the company’s...

on 18/6/21

2 min read